EUVIMEDEUVIMED entdecken
Crossref

Nuciferine ameliorates osteoarthritis: An in vitro and in vivo study

Maoxiu Peng, Guangjie Shen, Qiming Tu, Weihao Zhang, Juncheng Wang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Maoxiu Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, The Third Hospital Affiliated to Wenzhou Medical University, Rui'an 325200, China; Zhejiang Provincial Key Laborat…. Hauptthemen laut MEDLINE: Chondrocytes, Osteoarthritis, Interleukin-1beta, Mice, Inbred C57BL. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Wenzhou Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoarthritis (OA) is the most common musculoskeletal disease and a leading cause of pain and disability. A key hallmark of OA is cartilage degradation, which occurs due to an imbalance between the synthesis and degradation of the extracellular matrix (ECM). Interleukin-1β(IL-1β) has been reported to regulate ECM metabolism. Nuciferine (Nuc), a natural peptide extracted from the lotus leaf, possesses several significant pharmacological properties. However, the anti-inflammation of Nuc in OA has not been reported. In this study, ELISA and Western blot analyses were used to measure the production of inflammatory mediators in IL-1β-Induced mouse chondrocytes. Additionally, mice with or without surgical destabilization of the medial meniscus (DMM) were treated with intra-articular injection of Nuc. We found that Nuc significantly reduces the level of iNOS, PEG2, and IL-6 in IL-1β-induced chondrocytes. Furthermore, Nuc can ameliorate the development of OA in mice. Mechanistically, we found that the chondrocyte-protective effects of Nuc occur via the PTEN/NF-κB pathway. These findings suggest that Nuc could be a potential therapeutic agent for improving OA development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrocytesOsteoarthritisInterleukin-1betaMice, Inbred C57BLAnti-Inflammatory AgentsAnimalsMiceMaleCells, CulturedAporphinesNitric Oxide Synthase Type IINF-kappa BDisease Models, AnimalInterleukin-6Signal TransductionHumans

Stichwörter der Autor:innen

ChondrocytesInflammationNuciferineOsteoarthritisPTEN/AKT/NF-κB pathway

Substanzen

nuciferineInterleukin-1betaAnti-Inflammatory AgentsAporphinesNitric Oxide Synthase Type IINF-kappa BInterleukin-6

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, The Third Hospital Affiliated to Wenzhou Medical University, Rui'an 325200, China; Zhejiang Provincial Key Laboratory of Orthopaedics, Wenzhou, China.
  • Department of Orthopaedic Surgery, The Third Hospital Affiliated to Wenzhou Medical University, Rui'an 325200, China; Zhejiang Provincial Key Laboratory of Orthopaedics, Wenzhou, China. Electronic address: 171828633@qq.…

Förderung

  • Wenzhou Municipal Science and Technology Bureau

Zitieren

APA

Peng, M., Shen, G., Tu, Q., Zhang, W., & Wang, J. (2024). Nuciferine ameliorates osteoarthritis: An in vitro and in vivo study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113098

Vancouver

Peng M, Shen G, Tu Q, Zhang W, Wang J. Nuciferine ameliorates osteoarthritis: An in vitro and in vivo study. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113098

BibTeX
@article{Peng2024,
  author = {Peng, Maoxiu and Shen, Guangjie and Tu, Qiming and Zhang, Weihao and Wang, Juncheng},
  title = {Nuciferine ameliorates osteoarthritis: An in vitro and in vivo study},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113098}
}
Kostenlos starten →